|
|
|
|
X4 Pharmaceuticals Inc (NASDAQ: XFOR) |
|
|
|
| |
X4 Pharmaceuticals Inc's Working Capital Ratio
XFOR's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth
Current Liabilities decreased faster than X4 Pharmaceuticals Inc's Current Assets, this led to improvement in X4 Pharmaceuticals Inc's Working Capital Ratio to 3.7, Working Capital Ratio remained below X4 Pharmaceuticals Inc average.
Within Biotechnology & Pharmaceuticals industry 31 other companies have achieved higher Working Capital Ratio than X4 Pharmaceuticals Inc in first quarter 2025. While Working Capital Ratio total ranking has improved so far during the Q1 2025 to 388, from total ranking in the fourth quarter 2024 at 412.
Explain Working Capital Ratio
How much Current Assetss XFOR´s has?
What are XFOR´s Current Liabilities?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| XFOR Working Capital Ratio |
(Mar 31 2025)
Q1 |
(Dec 31 2024)
Q4 |
(Sep 30 2024)
Q3 |
(Jun 30 2024)
Q2 |
(Mar 31 2024)
Q1 |
| Y / Y Current Liabilities Change |
15.51 % |
30.06 % |
32.85 % |
51.46 % |
6.07 % |
| Y / Y Current Assets Change |
9.58 % |
-24.14 % |
-3.17 % |
78.59 % |
-32.13 % |
| Working Capital Ratio MRQ |
3.7 |
3.55 |
5.1 |
6.33 |
3.9 |
| XFOR's Total
Ranking |
# 388 |
# 412 |
# 820 |
# 670 |
# 769 |
| Seq. Current Liabilities Change |
-18.16 % |
12.8 % |
1.1 % |
23.75 % |
-7.85 % |
| Seq. Current Assets Change |
-14.69 % |
-21.54 % |
-18.5 % |
100.86 % |
-40.94 % |
| Working Capital Ratio first quarter 2025 Company Ranking |
| Within: |
No. |
| Biotechnology & Pharmaceuticals Industry |
# 32 |
| Healthcare Sector |
# 155 |
| Overall Market |
# 388 |
| Working Capital Ratio Statistics |
| High |
Average |
Low |
| 17.34 |
6.93 |
1.59 |
| (Mar 31 2020) |
|
(Mar 31 2019) |
Cumulative X4 Pharmaceuticals Inc's Working Capital Ratio
XFOR's Working Capital Ratio for the trailling 12 Months
XFOR Working Capital Ratio |
(Mar 31 2025)
12 Months |
(Dec 31 2024)
12 Months |
(Sep 30 2024)
12 Months |
(Jun 30 2024)
12 Months |
(Mar 31 2024)
12 Months |
| Y / Y Current Liabilities TTM Growth |
31.51 % |
29.4 % |
16.35 % |
8.77 % |
3.28 % |
| Y / Y Current Assets TTM Growth |
9.39 % |
-0.87 % |
20.28 % |
52.87 % |
42.39 % |
| Working Capital Ratio TTM |
4.65 |
4.72 |
5.4 |
5.84 |
5.59 |
| Total Ranking TTM |
# 1381
| # 1381
| # 3534
| # 2728
| # 2886
|
| Seq. Current Liabilities TTM Growth |
3.17 % |
7.13 % |
7.26 % |
10.94 % |
1.51 % |
| Seq. Current Assets TTM Growth |
1.61 % |
-6.45 % |
-0.84 % |
16.05 % |
-7.91 % |
News about X4 Pharmaceuticals Inc Working Capital Ratio |
|
X4 Pharmaceuticals Secures $125 Million Non-Dilutive Capital to Extend Cash Runway into Late 2025
X4 Pharmaceuticals Inc. recently announced a major capital infusion of $125 million, which includes $105 million from the sale of a Priority Review Voucher and a $20 million drawdown from an existing loan facility. This infusion of non-dilutive capital will extend the company s projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI (mavorixafor).
Despite a sequential decrease in current liabilities during the first quarter of 2024, X4 Pharmaceuticals Inc s working capital ratio deteriorated to 3.9, falling below the company s average of 7.46. When compared to 61 other companies within the industry, X4 Pharmaceuticals Inc ranked lower in terms of working capital ratio in the first quarter of 2024. However, the company has shown improvement, with a ranking of 619 compared to 6.08 in the third quarter of 2023.
|
On the trailing twelve months basis Due to decline in Current Liabilities in the Q1 2025 to $25.88 millions, cumulative Working Capital Ratio decreased to 4.65 below the average Working Capital Ratio. Working Capital Ratio is the average cumulative value over the last four quarters.
Among companies operating within Biotechnology & Pharmaceuticals industry 42 other companies have achieved higher Working Capital Ratio than X4 Pharmaceuticals Inc. While overall ranking is unchanged compared to the previous 12 months at no. 1381.
Explain Working Capital Ratio
How much Current Assetss XFOR´s has?
What are XFOR´s Current Liabilities?
| TTM Working Capital Ratio Company Ranking |
| Within: |
No. |
| Within the Biotechnology & Pharmaceuticals Industry |
# 43 |
| Healthcare Sector |
# 295 |
| Within the Market |
# 1381 |
| trailing twelve months Working Capital Ratio Statistics |
| High |
Average |
Low |
| 12.08 |
6.34 |
3.73 |
| (Jun 30 2020) |
|
(Sep 30 2022) |
|
Date modified: 2025-05-23T09:22:02+00:00
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
